Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation
Open Access
- 7 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 19 (16), 3190-3205
- https://doi.org/10.1093/hmg/ddq229
Abstract
We investigated the ability of AMP-activated protein kinase (AMPK) to activate PPARγ coactivator-1α (PGC-1α) in the brain, liver and brown adipose tissue (BAT) of the NLS-N171-82Q transgenic mouse model of Huntington's disease (HD). In the striatum of the HD mice, the baseline levels of PGC-1α, NRF1, NRF2, Tfam, COX-II, PPARdelta, CREB and ERRα mRNA and mitochondrial DNA (mtDNA), were significantly reduced. Administration of the creatine analog beta guanidinopropionic acid (GPA) reduced ATP and PCr levels and increased AMPK mRNA in both the cerebral cortex and striatum. Treatment with GPA significantly increased expression of PGC-1α, NRF1, Tfam and downstream genes in the striatum and cerebral cortex of wild-type (WT) mice, but there was no effect on these genes in the HD mice. The striatum of the untreated HD mice showed microvacuolation in the neuropil, as well as gliosis and huntingtin aggregates, which were exacerbated by treatment with GPA. GPA treatment produced a significant increase in mtDNA in the cerebral cortex and striatum of WT mice, but not in HD mice. The HD mice treated with GPA had impaired activation of liver PGC-1α and developed hepatic steatosis with accumulation of lipids, degeneration of hepatocytes and impaired activation of gluconeogenesis. The BAT in the HD mice showed vacuolation due to accumulation of neutral lipids, and age-dependent impairment of UCP-1 activation and temperature regulation. Impaired activation of PGC-1α, therefore, plays an important role in the behavioral phenotype, metabolic disturbances and pathology of HD, which suggests the possibility that agents that enhance PGC-1α function will exert therapeutic benefits in HD patients.Keywords
This publication has 87 references indexed in Scilit:
- Nutrient-dependent regulation of PGC-1α's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinNature Medicine, 2009
- Mitochondrial structural and functional dynamics in Huntington's diseaseBrain Research Reviews, 2009
- RETRACTED: Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy PhenotypeCell Metabolism, 2008
- Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life SpanCell Metabolism, 2008
- Transcriptional signatures in Huntington's diseaseProgress in Neurobiology, 2007
- Cardiac dysfunction in the R6/2 mouse model of Huntington’s diseaseNeurobiology of Disease, 2007
- Aging-Associated Reductions in AMP-Activated Protein Kinase Activity and Mitochondrial BiogenesisCell Metabolism, 2007
- Resveratrol improves health and survival of mice on a high-calorie dietNature, 2006
- Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibresNature, 2002